Most Popular
|
Newsletter
Breaking News
|
| Cyagen and Lumiere Therapeutics Forge Strategic Partnership to Advance Commercialization of the enCas12Ultra Base Editing System |
| Nov 18, 2024 |
| Recently, Cyagen (Suzhou) Biosciences Co., Ltd. ("Cyagen") signed a strategic cooperation agreement with Lumiere Therapeutics (Suzhou) Co., Ltd. ("Lumiere") to jointly advance the commercialization of Lumiere’s enCas12Ultra. Read More > |
|
Newsletter
Breaking News
|
| Cyagen's Partner InnoVec Receives US FDA Investigational New Drug Approval for IVB103 Clinical Trials |
| Aug 09, 2024 |
| On July 26, 2024, InnoVec's IVB103 injection received early Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), which may now proceed to the clinical trial phase. Read More > |
|
Breaking News
Newsletter
|
| Cyagen and Biointron Announce Strategic Alliance to Advance Antibody Drug Discovery |
| Mar 28, 2024 |
| Cyagen Biosciences (Suzhou) Inc. (“Cyagen Biosciences”) and Shanghai BaiYing Bio-Technology Co., Ltd. (“Biointron”) have signed a strategic cooperation agreement. Read More > |
|
Newsletter
Breaking News
|
| Cyagen Congratulates Our Partner INNOVEC on Receiving FDA Pediatric Rare Disease Designation (RPDD) for IVB102 Injection |
| Jan 23, 2024 |
| The United States Food and Drug Administration (FDA) granted Beijing InnoVec Biotherapeutics’ InnoVex IVB102 injection the Rare Pediatric Disease Designation (RPDD) on January 10, 2024. Innovec is now one step closer to being eligible for the Rare Pediatric Disease Priority Review Voucher (PRV) for the treatment of rare pediatric diseases with the InnoVex IVB102 injection in the United States. Read More > |
|
Breaking News
Newsletter
|
| HistoWiz and Cyagen Collaborate to Streamline Histopathology for Academic and Preclinical Mouse and Rat Model Research |
| Oct 23, 2023 |
| SALT LAKE CITY, Utah–AALAS 2023–Booth #2717– (October 23, 2023)--HistoWiz, a leading provider of histology and slide archiving services, and Cyagen Biosciences, an AI-enabled CRO company specializing in custom genetically engineered animal and cell models for research, announced today at the American Association for Laboratory Animal Science (AALAS) a strategic co-marketing partnership to streamline histopathology services. Read More > |
|
Breaking News
|
| YIMA and ZIP Solutions Announce Strategic Co-Marketing Agreement for Gene Therapy |
| Jun 08, 2023 |
| ZIP Solutions (Barcelona), a 100% affiliate of Biat Group (ticker BST), and YIMA Gene, a subsidiry under Cyagen Group, are please to announce a strategic co-marketing agreement for gene therapy. Read More > |
|
Breaking News
Newsletter
|
| Cyagen and Landau Strengthen Cooperation to Accelerate the Research and Development of AI-designed AAV Gene Therapy Vectors |
| Dec 12, 2022 |
| Recently, Cyagen and Guangdong Landau Biotechnology Co., Ltd. (hereinafter referred to as "Landau Biotech") strengthened their strategic partnership on the basis of the original strategic cooperation. Read More > |
|
Video
Newsletter
Breaking News
Q&A
|
| The First Artificial Chief Scientific Officer: AI Marvin |
| Nov 21, 2022 |
| Have you ever wondered what the future of science education looks like? Many envision a future of readily accessible science knowledge and facts presented by intelligent, interactive teachers. Read More > |
|
Breaking News
|
| Cyagen and Neurophth Enter Global Strategic Collaboration to Develop AI-Designed AAV Gene Therapy Vectors for Ophthalmic Disorders |
| Nov 08, 2022 |
| Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders. Read More > |
|
Newsletter
Breaking News
|
| Taconic-Cyagen Custom Animal Model Awards (CAMA) Announces 6 Winners |
| May 14, 2021 |
| We are delighted to announce the winners of the first Taconic-Cyagen Custom Animal Model Awards (CAMA) competition. Read More > |
